Marlborough-based Sunovion Pharmaceuticals announced it has secured U.S. Food and Drug Administration approval for two new uses of its Latuda drug.
According to Sunovion, the FDA said Latuda can be used alone or as a secondary treatment with lithium or valproate to treat adult patients who have major depressive episodes associated with bipolar depression. Latuda is also used to treat schizophrenia in adults.
“These two approvals represent a significant milestone not only for Sunovion and (Dainippon Sumitomo Pharma Co.), but for the millions of Americans who are living with bipolar disorder and struggling to manage the symptoms of bipolar depression,” said Masayo Tada, representative director, president and CEO of Dainippon Sumitomo Pharma Co. (DSP), the parent company of Sunovion. “We look forward to building on the strong foundation started in the United States to bring Latuda to other markets around the world.”
Read more
In Reverse Decision, Sunovion Wins Patent Infringement Suit
